ClinicalTrials.gov
ClinicalTrials.gov Menu

Micro-RNA Expression Profiles in High Risk Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01220427
Recruitment Status : Terminated
First Posted : October 13, 2010
Last Update Posted : March 3, 2016
Sponsor:
Collaborator:
Universitaire Ziekenhuizen Leuven
Information provided by:
Wuerzburg University Hospital

Brief Summary:
The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.

Condition or disease
Prostate Cancer Radical Prostatectomy

Study Type : Observational
Estimated Enrollment : 300 participants
Time Perspective: Retrospective
Official Title: Micro-RNA Expression Profiles in High Risk Prostate Cancer
Study Start Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Group/Cohort
Clinical high-risk prostate cancer, radical prostatectomy



Primary Outcome Measures :
  1. Recurrence free survival [ Time Frame: Yearly update until clinical progression ]
    The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.


Secondary Outcome Measures :
  1. Cancer specific survival [ Time Frame: Yearly update until death ]
    The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly until death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
University hospital, community hospital
Criteria

Inclusion Criteria:

Patients with clinically localised high risk prostate cancer (cT>2, bx GS >7, PSA >20 ng/ml) scheduled for radical prostatectomy.

Exclusion Criteria:

Non high risk prostate cancer


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01220427


Locations
Germany
Department of Urology and Pediatric Urology University Hospital Würzburg
Würzburg, Germany, 97080
Sponsors and Collaborators
Wuerzburg University Hospital
Universitaire Ziekenhuizen Leuven

Responsible Party: Martin Spahn, University Hospital Würzburg
ClinicalTrials.gov Identifier: NCT01220427     History of Changes
Other Study ID Numbers: mi-RNA HR-Pca
First Posted: October 13, 2010    Key Record Dates
Last Update Posted: March 3, 2016
Last Verified: August 2010

Keywords provided by Wuerzburg University Hospital:
high-risk prostate cancer
radical prostatectomy
micro-RNA

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases